Sulfonamide Derivatives for Selective Bradykinin B1 Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bradykinin B1 receptor antagonists often have undesirable side effects due to lack of selectivity for B1 over B2 receptors, leading to ineffective pain management in chronic inflammatory conditions.
Innovation Solution
Development of new sulfonamide derivatives with high affinity for bradykinin B1 receptors and selectivity over B2 receptors, reducing unwanted side effects and enhancing therapeutic efficacy in pain management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective bradykinin receptor antagonists are used, then pain management coverage is broad, but side effects increase due to B2 receptor blockade
Solution Approach 1:
The patent applies local quality by designing the sulfonamide derivative molecule with specific structural features (substituents at defined positions on the aromatic ring) that confer selective affinity for B1 receptors over B2 receptors. This molecular-level differentiation allows the drug to target specific receptor subtypes, achieving pain management through B1 blockade while avoiding B2-mediated side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations on the sulfonamide core structure) to optimize receptor selectivity. By adjusting these chemical parameters, the invention achieves high B1 selectivity while maintaining analgesic efficacy, thereby resolving the contradiction between broad pain management and side effect reduction.
2Object-affected harmful factors
If B1 selective antagonists are developed, then side effects are reduced, but selectivity and affinity must be precisely optimized
Solution Approach 1:
The patent applies segmentation by dividing the molecular optimization process into distinct structural components: the sulfonamide core, aromatic substituents, and their relative positions. Each component can be independently optimized for B1 selectivity, allowing systematic development of high-selectivity analogs without requiring complete redesign of the entire molecule.
Solution Approach 2:
The patent employs composite materials by combining different chemical moieties (sulfonamide group, aromatic rings, various substituents) into a composite molecular structure. This composite approach allows the integration of multiple functional elements that collectively provide high B1 selectivity and affinity, resolving the challenge of achieving precise selectivity optimization.
3Reliability
If sulfonamide derivatives are designed for high B1 affinity, then therapeutic efficacy improves, but structural complexity increases
Solution Approach 1:
The patent applies taking out by isolating and optimizing the essential functional elements required for B1 affinity (the sulfonamide core with specific aromatic substituents) while eliminating unnecessary structural complexity. This extraction of core functional features maintains high therapeutic efficacy while simplifying the overall molecular architecture compared to more complex peptide-based antagonists.
Data Source
AI summary
The present invention relates to new sulfonamide derivatives of formula (I), wherein R1 -R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.